PLATELET DISORDERS Joanna Rupa-Matysek.

Slides:



Advertisements
Similar presentations
Coagulation: Review & Lab techniques
Advertisements

Platelet Thrombocytes.
Heather D. Mannuel, MD, MBA March 12, 2008
1 Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Normocytic Anemia Dr. Fatin Al-Sayes, MD, MSc, MRCPath Consultant Hematology / Assistant Professor King Abdulaziz University Hospital.
Hemorrhagic diseases. Lesions of the blood vessels Lesions of the blood vessels Abnormal platelets Abnormal platelets Abnormalities in the coagulation.
Bleeding disorders Doc. MUDr. L. Boudová, Ph.D.. Bleeding disorders I. Vessels - increased fragility II. Platelets - deficiency or dysfunction III.Coagulation.
BLEEDING DISORDERS AN OVERVIEW WITH EMPHASIS ON EMERGENCIES.
PLATELETS. PLETELET PHYSIOLOGY Platelets Production: Hematopoietic stem cell  Megakaryoblast  Megakaryocyte  Fragmentation of cytoplasm Platelets.
Hemostatic System - general information Normal hemostatic system –vessel wall –circulating blood platelets –blood coagulation and fibrynolysis Platelets.
Hemostasis & Thrombosis: Platelet Disorders Beth A. Bouchard BIOC 212: Biochemistry of Human Disease Spring 2005.
KANUPRIYA CHATURVEDI 1.  1. Explain the relationship between platelet count and bleeding risk.  2. State the underlying pathologic mechanisms that may.
DISORDERS OF PRIMARY HEMOSTASIS
PLATELET DISORDERS. Bleeding due to thrombocytopenia or abnormal platelet function is characterized by purpura and bleeding from mucous membranes. Bleeding.
Platelet Disorders. Platelets *Disc shape cells 2-4 mm in diameter. *They have blue grey cytoplasm with red lysosomal granules, but devoid of nuclei.
HEMOSTASIS/THROMBOSIS II Congenital/Acquired Hemorrhagic Disorders & Their Treatment.
C-Slide 1 Thrombocytopenia By Dr. Hanan Said Ali.
Bachelor of Chinese Medicine, The University of Hong Kong Bleeding disorders Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University.
Haemostasis Tiffany Shaw MBChB II Haemostasis Pathway Injury Collagen exposure Tissue Factor Platelet adhesion Coagulation Cascade Release reaction.
Bleeding and coagulation disorders
IMMUNE THROMBOCYTOPENIA Cathy Payne MSN, ACNP-BC Hematology/Oncology Nurse Practitioner Ironwood Cancer and Research Centers.
Gatmaitan, Raymond Vincent Golpeo, Kirsten C.
PLATELETS AND HEMOSTASIS
ITP Immune (Idiopathic) Thrombocytopenic Purpura AM Report 5/25/2010.
MLAB C OAGULATION K ERI B ROPHY -M ARTINEZ Coagulation Disorders: Primary Hemostasis.
Dr.Leni Lismayanti, SpPK Dept of Clinical Pathology RSHS/FKUP Bandung
HEMOSTASis Nada Mohamed Ahmed , MD, MT (ASCP)i.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
THROMBOCYTOPENIA - reduced platelet count -. First of all.. what are platelets? Platelets: tiny cells that circulate in the blood and whose function is.
Autoimmune Idiopathic Thrombocytopenic Purpura (ITP) Nicola Davis.
Bleeding Disorders Dr. Farjah H.AlGahtani
Approach to Bleeding Disorders
HIV and haematology Mike Webb Division of Clinical Haematology 5 March 2011.
Quantitative and qualitative platelet disorders
Bleeding Disorders JANUARY 19, 2012 Erin M. Kwolek.
Coagulation / Coagulopathies. Hemostasis Hemostasis is the ability of the body’s systems to maintain the integrity of the blood and blood vessels. Hemostasis.
HIV and haematology Mike Webb Division of Clinical Haematology 8 Feb 2010.
Hemorrhagic diatheses in children. Gastrointestinal bleedings. Sakharova I. Ye., MD, PhD.
Bleeding and Kristine Krafts, M.D. Thrombotic Disorders.
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
Von Willebrand Disease
Hemostatic process 1- Vascular Consrriction 2- Platelet plug formation 3- Fibrin formation ( Coagulation ) 4- Fibrinolysis.
1 CASE REPORT hematology Monika Csóka MD, PhD year old boy no abnormalities in previous anamnesis 2 weeks before viral infection (fever, coughing)
Thrombocytopenia Sheryl L. Ziegler, D.O Hemostasis Subendothelial matrix Platelets Hemostatic plug Fibrin Endothelial cell RBC WBC WBC.
Nursing Management: Hematologic Problems Chapter 31 Overview Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Thrombocytopenia Chapter 31 Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Approach to the Bleeding Child. Evaluation  History Current Bleeding Medical Family  Physical exam  Selected laboratory investigations.
Coagulation tests CBC- complete blood count
Abnormal bleeding in children J Kiwanuka. GENERAL INTRODUCTION.
Chapter 22. Bleeding trait and disorders O bleeding trait: spontaneous bleeding, bruising, purpura O cause: vessel defect, platelet defect, coagulation.
THROMBOCYTOPENIA Reduction in platelet count below 150 x 109
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
II. Antiplatelet Drugs.
Congenital bleeding disorders
Inherited disorders of platelet function
Bleeding disorders Dr. Feras FARARJEH.
Platelets disorders.
Disorders of Hemostasis
Diagnosis Approach of Bleeding in Children ________________________________ Ketut Ariawati Hematologi Onkologi RSUP Sanglah Denpasar.
Constituents of the blood: Platelets and plasma
Approach to Thrombocytopenia
platelet function:    1- Adhesion — the deposition of platelets on the .
The Fascinating World of Haemostasis and Thrombosis
Bleeding and Thrombotic Disorders Kristine Krafts, M.D.
Bleeding disorders Dr. Feras FARARJEH.
Drugs Affecting Blood.
Dr. Hasan Fahmawi, MRCP(UK), FRCP(Edin).
Approach to Bleeding Disorders DR
ABNORMAL HEMOSTASIS September 19, :30-10:30 am
Presentation transcript:

PLATELET DISORDERS Joanna Rupa-Matysek

Hemostatic System - general information Normal hemostatic system vessel wall circulating blood platelets blood coagulation and fibrynolysis

Bleeding Diathesis inherited or acquired defects of vessel wall platelets number and/or function coagulation system

PRIMARY HEMOSTASIS DISORDERS Immediate bleeding after trauma, cuts and surgical and dental procedures Mucocutaneous bleeding: petechia, easy bruising, nosebleeds, gingival bleeding, heme-positive stools, hematuria, menorrhaga Secondary Hemostasis Disorders: delayed bleeding from cuts or injuris, hemarthroses and intramuscular hematomas, deep soft tissue bleeds, intracranial hemorrages

PLATELETS Anucleate disc-shape cell fragments arise from megakariocytes in bone marrow 1/3 of platelets are sequestrated in the spleen other 2/3 circulate for 7-10 days responsible for primary hemostasis - they adhere to damaged blood vessels, aggregate one with another and facilitate the generation of thrombin normal platelet count : 150-450 G/l 5

Platelets Disorder Disorder of platelet number thrombocytopenia thrombocytosis Disorder of platelet function

Platelets Disorder - signs and symptoms asymptomatic if platelets count > 50 G/l onset of bleeding after trauma - immediate sites of bleeding superficial: skin, mucous membranes, nose, genitourinary tract physical finding - petechiae, ecchymoses

Platelet structure Α-Granules GPIIb-IIIa – fibrinogen receptor - plasma (surface) membrane protein: GPIIb-IIIa – fibrinogen receptor GP Ib-IX-V: vWF receptor GPIa-IIa: collagen receptor - secretory granules: Α-Granules Dense granules Lysosomes 8

Platelet receptors in clinical practice Cyclooxygenase inhibitors (TXA2 –e.g. Aspirin) Adenosine diphosphate inhibitors -ticlopidine hydrochloride (Ticlid), clopidogrel bisulfate (Plavix) GPIIb-IIIa receptor antagonists Abciximab, Epifibatide, Tirofiban

Disorder of platelets function 1 defects of platelet adhesion inherited: vonWillebrand’s disease, Bernard-Soulier syndrome acquired: uremia

Disorder of platelets function 2 defects of platelet aggregation inherited: Glantzmann’s thrombasthenia acquired: dysproteinemia, drug ingestion (ticlopidin)

Disorder of platelets function 3 defects of platelet release inherited: grey-platelet, Hermansky-Pudlak, Chediac-Higashi syndr. acquired: cardiopulmonary bypass, myeloproliferative disorders, drugs 12

Platelet function tests Platelet count – in vitro clumping caused by EDTA- dependant agglutinins Morphology Platelet aggregations -ADP, -collagen, -ristocetin RIPA PFA-100

Therapy Platelet transfusion should be used only in severe bleeding episodes Recombinant factor VIIa Antifibrynolytic agents (tranexamic acid) Desmopressin (DDAVP)

Thrombocytopenia A. Decreased marrow production of megakariocytes congenital disorders acquired disorders B. Splenic sequestration of circulating platelets C. Increased destruction of circulating platelets (congenital/acquired disorders) immune destruction nonimmune destruction

Thrombocytopenia (A) A. Decreased marrow production of megakariocytes congenital disorders Fanconi’s anemia thrombocytopenia with absent radii (TAR) acquired disorders marrow infiltration with malignant cells marrow fibrosis aplastic and hypoplastic anemias (idiopathic, drugs, toxins ) deficiency states (vitamin B12, folate, iron ) paroxysmal nocturnal hemoglobinuria

Thrombocytopenia (B) B. Splenic sequestration of circulating platelets splenic enlargement due to tumor infiltration splenic enlargement due to portal hypertension

Thrombocytopenia (C) C. Increased destruction of circulating platelets congenital disorder Wiscott-Aldrich syndrome, Bernard-Soulier syndrome acquired disorders nonimmune destruction DIC hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura sepsis vascular prostheses, cardiac valves immune destruction Primary immune thrombocytopenic (ITP) drug-induced thrombocytopenia chronic autoimmune disorders infection (HIV) malignancies

PRIMARY IMMUNE THROMBOCYTOPENIA – ITP (Idiopathic Thrombocytopenic Purpura) The most common cause of isolated thrombocytopenia defined as a peripheral blood platelet count less than 100G/L No associated condition or other causes of thrombocytopenia Shortened intravascular survival of platelets due to destruction caused by antiplatelet antibodies

PRIMARY IMMUNE THROMBOCYTOPENIA Clinical features petechiae ecchymoses mucose membranes bleeding menorrhagia rare internal, intracranial bleeding

PRIMARY IMMUNE THROMBOCYTOPENIA Diagnosis is one of exclusion platelet count <100G/l bleeding time - usually normal peripheral blood smear - large platelets bone marrow examination - normal or increased number of megakariocytes H. pylori (-), HIV (-), HCV (-)

Treatment of ITP corticosteroids permanent responses - 30% not necessary unless platelets count > 30G/L or there is extensive bleeding corticosteroids permanent responses - 30% prednisone 1mg/kg for 4-6 weeks splenectomy permanent responses - 60% immunosuppresive drugs rituximab intravenous immunoglobulins anti-Rh (D) Immune Globulin other – danazol Thrombopoietin (TPO) receptor agonists (romiplostim, eltrombopag)

Thrombocytosis Thrombocytosis resulting from myeloproliferation essential thrombocythemia polycythemia vera chronic myelogenous leukemia myeloid metaplasia Secondary (reactive) thrombocytosis systemic inflammation malignancy iron deficiency hemorrhage postsplenectomy 23

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) caused by antibodies directed against heparin in complex with platelet factor 4 50% or more reduction in platelet count Beginning 5 or more days after first exposure to heparin Thrombotic complications Therapy – to discontinue all forms of heparin Direct IIa inhibitors (lepirudin, argatroban) and Xa (danaparoid)

Thrombotic Thrombocytopenic Purpura (TTP) Syndrome of consumptive thrombocytopenia, pentad abnormalities: 1/ thrombocytopenia 2/ microangiopathic hemolitic anemia 3/ renal failure 4/ neurologic abnormalities 5/ fever Deficiency of metalloprotease ADAMTS 13 Prompt plasma exchange

Case presentation